Auranofin inhibits histamine release from rat peritoneal mast cells.
The effect of auranofin on histamine release from immunologic and non-immunologic activated rat peritoneal mast cells cocultured with 3T3 fibroblasts (MC/3T3) was investigated. When MC/3T3 were preincubated with 2 x 10(-5) M auranofin and thereafter challenged with anti-IgE antibodies, a maximal inhibition of histamine release (86.2%) was obtained. Non-immunological histamine release induced by compound 48/80, substance P and bradykinin was inhibited to a lesser degree, i.e. 36.0%, 37.6% and 24.0% respectively. Simultaneous incubation of auranofin and the stimulating agents resulted in a higher inhibition of histamine release: anti-IgE antibodies--92.0%; compound 48/80--73.5%; substance P--46.1%. We conclude that auranofin effectively reduces histamine release from immunologic and non-immunologic activated mast cells. This may be relevant to the control of allergic reactions.
Department of Medicine A, Hadassah Medical School, Hebrew University, Jerusalem.
M
M
Shalit
F
F
Levi-Schaffer
D000818:Animals; D001310:Auranofin / Q000494:pharmacology*; D001920:Bradykinin / Q000494:pharmacology; D002478:Cells, Cultured; D005347:Fibroblasts / Q000187:drug effects / Q000378:metabolism; D006636:Histamine Release / Q000187:drug effects*; D008213:Lymphocyte Activation / Q000187:drug effects; D008297:Male; D008407:Mast Cells / Q000187:drug effects* / Q000378:metabolism; D010529:Peritoneal Cavity / Q000166:cytology; D051381:Rats; D013373:Substance P / Q000494:pharmacology; D003189:p-Methoxy-N-methylphenethylamine / Q000494:pharmacology
D013373:Substance P; D001310:Auranofin; D003189:p-Methoxy-N-methylphenethylamine; D001920:Bradykinin